SCHEMBL7037516

SCHEMBL7037516

C1=CN=C(c2ccncc2)[N]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
LMNA P02545 2/20 0.48
NOTUM Q6P988 1/20 0.40
QDPR P09417 1/20 0.37
DDAH1 O94760 1/20 0.36
NOS1 P29475 1/20 0.36
TP53 P04637 1/20 0.36
PKM P14618 1/20 0.36
KIF11 P52732 2/20 0.34
CYP2D6 P10635 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
PABPC1 P11940 1/20 0.33
APOBEC3A P31941 1/20 0.33
EIF4H Q15056 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481996 0.73 CYP1A2 (0.39) LMNANOTUMKDM4ECYP1A2GAA
SCHEMBL5034958 0.73 RAB9A (0.38) NOTUMTP53KDM4ESMN1; SMN2ALDH1A1
SCHEMBL5111459 0.73 TDP1 (0.38) MAPTLMNANOTUMTP53PKM
SCHEMBL4861976 0.73 CYP2A6 (0.56) MAPTLMNATP53KIF11CYP2D6
SCHEMBL9465032 0.70 CYP2A6 (0.42) CYP3A4CYP2C9CYP2C19
SCHEMBL9728 0.67 MAPT (1.00) MAPTLMNANOTUMQDPRDDAH1
SCHEMBL7175606 0.66 APP (0.46) MAPTLMNANOTUMKDM4ECYP1A2
SCHEMBL9465289 0.65 ERN1 (0.33) TP53CYP2D6CYP1A2CYP3A4MEN1
SCHEMBL5578453 0.65 MAPT (0.48) MAPTLMNANOTUMQDPRDDAH1
Hydrochloric Acid SCHEMBL3930145 0.65 MAPT (0.92) MAPTLMNANOTUMQDPRDDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030100742-A1 Useful as antibacterial and antiprotozoal agents in mammals, fish and birds; contains a carbamate-containing fused ring PFIZER INC. 2003-05-29 US claimed
EP-1146051-A2 Erythromycin A derivatives Pfizer Products Inc. (US) 2001-10-17 EP claimed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 WO disclosed
US-20030100742-A1 Useful as antibacterial and antiprotozoal agents in mammals, fish and birds; contains a carbamate-containing fused ring PFIZER INC. 2003-05-29 US disclosed
EP-1146051-A2 Erythromycin A derivatives Pfizer Products Inc. (US) 2001-10-17 EP disclosed
US-5246914-A Fungicides and plant growth regulators BASF AKTIENGESELLSCHAFT (DE) 1993-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100742-A1 Useful as antibacterial and antiprotozoal agents in mammals, fish and birds; contains a carbamate-containing fused ring CASP1, CPS1, CASP10 MAPT 757/4885LMNA 1722/4885NOTUM 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.